[ad_1]
A new mixture of the two antibodies, known as AZD7442, “statistically significantly reduced the number of severe COVID-19 cases or death” from the disease among non-hospitalized patients who initially developed mild to moderate symptoms, AstraZeneca said in a statement.
The company is conducting a final third phase of clinical trials of a new antibody preparation to assess its safety and efficacy.
“As severe COVID-19 cases continue around the world, there is a marked need for new treatments, such as AZD7442, to protect vulnerable populations … that can help prevent progression to serious disease,” said lead researcher Hugh Montgomery.
“These positive results suggest that the correct intramuscular dose of AZD7442 could play an important role … in the fight against a devastating pandemic,” he emphasized.
The study involved 903 people and 90 percent. they belonged to a high-risk group in terms of developing severe COVID-19.
The AstraZeneca vaccine against COVID-19, developed separately with the University of Oxford, has helped the UK run a rapid vaccination campaign against the disease.
[ad_2]
